UPDATE: Gilead Sciences (GILD) PT Lowered to $63 but Morgan Stanley Notes Clinical Hold Lifting is a Positive
Tweet Send to a Friend
(Updated - April 12, 2022 7:43 AM EDT)
Morgan Stanley analyst Matthew Harrison lowered the price target on Gilead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Morgan Stanley analyst Matthew Harrison lowered the price target on Gilead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
